Launched in February, Gugutam is expected to be available for sale for seven years
[by Yu, Suin] Hanmi Pharmaceutical (hereinafter referred to as Hanmi Pharm)'s combination drug for treating benign prostatic hyperplasia and erectile dysfunction, 'Gugutams,' has been fully launched in the Mexican market under the local brand name 'Aditams.'
카지노 바카라 Pharm announced on March 27 the successful launch of Gugutams in Mexico in February, following an export agreement with the Mexican pharmaceutical company Silanes. The company intends to market the product in Mexico for the next seven years.
Gugutams, developed by 카지노 바카라 Pharm, is the 'world's first' combination treatment for urological diseases, combining 'tamsulosin,' a treatment for benign prostatic hyperplasia, and 'tadalafil,' a treatment for erectile dysfunction. It has garnered attention as the first Korean prescription drug to use 'Poly-Cap' technology, which enables the combination of multiple active ingredients in a single capsule.
The company highlights that Gugutams is the first combination drug for urological diseases to be introduced to the Mexican market and is anticipated to offer a new treatment option for patients suffering from both benign prostatic hyperplasia and erectile dysfunction. Additionally, the company explained that by managing two major conditions simultaneously with a single drug, Gugutams is expected to enhance patient convenience and maximize treatment efficacy.
Founded in 1943, Silanes is a leading pharmaceutical company in Mexico, recognized for its strengths in innovative healthcare solution research and development (R&D), production, and commercialization. The company has established itself as a key player in the Latin American pharmaceutical market, supported by a robust distribution network and strategic collaborations with global partners.
In 2023, Silanes successfully launched the hypertension and hyperlipidemia combination drug 'Amosartan Q' under the local brand 'Lodarta' in collaboration with 카지노 바카라 Pharm. In 2024, it introduced the hypertension combination drug 'Amosartan Plus' under the local brand 'Bicartial-CTD' in the Latin American market. Following these products, Gugutams will become the third 카지노 바카라 Pharm product to be sold in the vast region.
카지노 바카라 Pharm is focusing on expanding its partnerships in emerging markets, such as the Middle East and Latin America, in addition to advanced markets like North America and Japan. The company aims to broaden its collaborative product portfolio, using these regions as strategic entry points. “As the first urological disease combination treatment to enter the Mexican market, Gugutams will introduce a new treatment paradigm for local patients,” said Park Jae-hyun, CEO of 카지노 바카라 Pharmaceutical. “Through our collaboration with Silanes, we will strengthen 카지노 바카라 Pharm’s position in the Latin American market and use this partnership as a stepping stone to boost our global competitiveness.”